Inclusion Body Myositis Treatment Market: By Molecule Type (ACE-083, Aceneuramic Acid ER, ALZ-1903, UX-001P, UX-007, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and forecast to 2030.

Inclusion Body Myositis Treatment Market was valued at USD 6,224.1 million in 2023 and is expected to grow at an 5.2% CAGR from 2024 to 2030. Inclusion Body Myositis (inclusion body myositis) is a rare and serious muscle disease. It causes inflammation and damage to the muscles, which can lead to weakness and difficulty walking, climbing stairs, or using your hands. inclusion body myositis most often affects people aged 50 years or older. They are more common in men than women. The market is driven by factors such as the increasing incidence of Inclusion Body Myositis due to growing awareness about the disease and its symptoms. Moreover, there is a significant amount of growing population of aging individuals, who are more susceptible to inclusion body myositis. Thus, the rising prevalence of autoimmune diseases that predispose individuals to inclusion body myositis development is likely to result in better treatment options for the disease in the future, driving the growth of the inclusion body myositis treatment market. Additionally, the development of biomarker assays and genetic testing holds promise for personalized treatment approaches. Increasing awareness among healthcare professionals serves as a pivotal driver for the growth of the inclusion body myositis Treatment market. Continuous medical education programs and collaborative efforts among healthcare organizations play a crucial role in disseminating knowledge about inclusion body myositis, empowering healthcare professionals to deliver optimal care and support to affected individuals.

However, the capital-intensive nature of developing treatments and therapies acts as an entry barrier, deterring potential market entrants. In addition to advancements in disease understanding, regulatory incentives for orphan drug development have played a pivotal role in driving growth opportunities in the global inclusion body myositis Treatment market. Governments and regulatory agencies worldwide have implemented policies and incentives to incentivize the development of therapies for rare diseases like inclusion body myositis. These incentives include expedited review processes, extended market exclusivity periods, and financial incentives such as tax credits and grants. Such regulatory support has attracted pharmaceutical companies to invest in orphan drug development and treatment for inclusion body myositis, leading to a surge in the number of therapeutic candidates in various stages of clinical development. The latest trend in the global Inclusion Body Myositis Treatment market is a significant shift towards collaborative efforts between academia and industry for drug development.

Key Developments: 

• In January 2021, Abcuro announced that it had raised $42 million in a Sanofi Ventures-led series A to advance anti-KLRG1 treatments for autoimmune diseases and cancers. The funding was intended to be used to conduct a proof-of-mechanism clinical trial in patients with sporadic inclusion body myositis (inclusion body myositis)